Back to Search
ANDREW ZELENETZ, MD
MD
Medical Oncology Physician
NPI: 1841261351IndividualAccepts Medicare
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
185762(NY)
Education
HARVARD MEDICAL SCHOOL
Class of 1984
Research & Publications (20)
Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma.
PMID 12736224·Ann Oncol·2003
6-review
A clinical and scientific overview of tositumomab and iodine I 131 tositumomab.
PMID 12728404·Semin Oncol·2003
6-review
Risk models for chemotherapy-induced neutropenia in non-Hodgkin's lymphoma.
PMID 14682115·Oncology (Williston Park)·2003
6-review
Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma.
PMID 19624539·Br J Haematol·2009
3-trial
Follicular lymphoma in the United States: first report of the national LymphoCare study.
PMID 19204203·J Clin Oncol·2009
8-other
Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project.
PMID 19264918·Blood·2009
4-observational
The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphoma.
PMID 19139730·Bone Marrow Transplant·2009
8-other
Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase 2 clinical trial.
PMID 19220284·Br J Haematol·2009
3-trial
Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies.
PMID 19652067·J Clin Oncol·2009
3-trial
Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses.
PMID 19075280·J Clin Oncol·2009
4-observational
NCCN task force report: molecular markers in leukemias and lymphomas.
PMID 19635230·J Natl Compr Canc Netw·2009
6-review
Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma.
PMID 19438504·Br J Haematol·2009
8-other
Synchronous presentation of systemic and brain non-Hodgkin lymphoma.
PMID 19052988·Leuk Lymphoma·2008
8-other
Lymphoid malignancies: a decade and a half of dramatic improvements in outcome.
PMID 18952542·Clin Lymphoma Myeloma·2008
8-other
Comparison of referring and final pathology for patients with non-Hodgkin's lymphoma in the National Comprehensive Cancer Network.
PMID 18768434·J Clin Oncol·2008
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1275 YORK AVE
NEW YORK, NY 10021 - Phone
- (212) 639-2656
Quick Facts
- NPI
- 1841261351
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 42
- Publications
- 20
Are you this provider?
Claim Your Profile